top of page

Foveal LLP Independent Investment Research Foveal Research

prescient biotech & pharma global equity research

Independent Investment Research

User

< Back

IgAN- VERA/Otsuka/VRTX/NOVN: Hi Amit, Fabhalta spoils the BAFF/APRIL party

As predicted, FDA apporved orla Fabhalta spoils the BAFF/APRIL party

As highlighted in our last quarter update, Novartis' already IgAN FDA-approved Fabhalta met its phase III, significantly raising the bar for the new class of BAFF/APRIL alternatives sibeprenlimab (Otsuka), atacicept (VERA) and VRTX (povetacicept).

bottom of page